What are the top-selling drugs of Alexion?

Overview of Alexion Pharmaceuticals 
Alexion Pharmaceuticals has established itself as a global leader in the development, commercialization, and marketing of high-value therapies targeting rare and ultra-rare diseases. Founded in 1992 and headquartered in Boston, Massachusetts, Alexion’s journey began as a startup focused on harnessing the complex biology of the complement cascade to address life-threatening conditions. Over more than 25 years of operations, the company has honed its expertise—and built a robust pipeline—primarily leveraging its deep understanding of immunology and complement biology to craft innovative therapies tailored for patients suffering from rare, devastating diseases. The company’s history is marked by continuous evolution: from early breakthroughs in complement inhibition to subsequent diversification into enzyme replacement therapies. Moreover, following its acquisition by AstraZeneca for $39 billion in 2021, Alexion’s strategic trajectory has further emphasized global expansion, integration of research capabilities, and a bolstered presence in immunology alongside its established expertise in rare diseases. 

Key Therapeutic Areas 
Alexion remains singularly focused on addressing unmet medical needs in several core therapeutic domains by leveraging its knowledge of the complement system. The company’s portfolio reflects its commitment to rare diseases and includes treatments for disorders with limited or no alternative therapies. Its main areas of focus include: 
- Hematology: Specifically addressing paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) with innovative complement inhibitors. 
- Neurology: Offering treatments for diseases such as neuromyelitis optica spectrum disorder (NMOSD) and antibody-mediated generalized myasthenia gravis (gMG). 
- Metabolic Disorders: Delivering life-changing enzyme replacement therapies for ultra-rare metabolic conditions such as hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). 
- Other Areas: Including but not limited to potential applications in cardiology, nephrology, and ophthalmology; these reflect the company’s broader ambitions to address diverse facets of immune dysfunction and complement-mediated conditions. 

Top-Selling Drugs of Alexion

List of Top-Selling Drugs 
Alexion’s commercial success is closely tied to a handful of blockbuster therapies that have defined its market presence and driven revenue growth. The company’s leading products include: 

1. Soliris (eculizumab) 
Soliris is a first-in-class complement inhibitor that targets complement component C5. Initially approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), it later expanded to treat a broader range of complement-mediated disorders including atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). 

2. Ultomiris (ravulizumab) 
Ultomiris is designed as a next-generation C5 complement inhibitor and constitutes a significant evolution over Soliris. With a longer half-life that allows for dosing once every eight weeks—compared to the more frequent dosing required with Soliris—it offers improved patient compliance and quality of life. Ultomiris has rapidly gained approval in several markets and now forms a critical component of Alexion’s portfolio in treating PNH and aHUS, among other conditions. 

3. Strensiq (asfotase alfa) 
Strensiq is an enzyme replacement therapy specifically indicated for patients with pediatric-onset hypophosphatasia (HPP), a rare metabolic disorder characterized by defective bone mineralization. As a relatively newer addition to the portfolio that has also achieved impressive sales, Strensiq uniquely reinforces Alexion’s commitment to ultra-rare disease treatments. 

4. Kanuma (sebelipase alfa) 
Kanuma is another enzyme replacement therapy, approved for treating lysosomal acid lipase deficiency (LAL-D), a condition that otherwise leads to severe metabolic complications. Although its sales volume is smaller relative to Soliris and Ultomiris, Kanuma’s presence in the portfolio is vital for maintaining a diversified revenue stream in the metabolic disorder segment. 

Sales Data and Market Performance 
Alexion’s top-selling drugs have generated significant revenues over the years, reflecting not only their clinical impact but also the company’s market dominance, particularly in rare diseases: 

- Soliris: 
Soliris has historically been the cornerstone of Alexion’s revenue. As per detailed financial disclosures, Soliris accounted for approximately $3.1 billion in revenue in a standalone period with some reports indicating net product sales of over $4 billion in certain periods. Even amidst emerging competition and an environment characterized by pricing pressures, Soliris has maintained robust sales figures and remains the flagship therapy owing to its first-mover advantage in the complement inhibition space. The product’s high cost per patient annually—sometimes reported at figures exceeding $500,000 per year—further compounds its market impact despite potential competitive biosimilar threats. 

- Ultomiris: 
Ultomiris, introduced as a follow-on to Soliris, has experienced accelerated commercial uptake. Notably, sales of Ultomiris increased dramatically, with some reports indicating a growth rate of 218% over a previous period as it captured a broader share of the PNH and aHUS markets due to its less frequent dosing schedule. The design improvements that allowed for bimonthly dosing have contributed substantially to both patient adherence and a favorable market reception—ultimately raising revenue appreciably and positioning Ultomiris as a central pillar in Alexion’s commercialization efforts. 

- Strensiq and Kanuma: 
While both Strensiq and Kanuma generate lower absolute revenue compared to the complement inhibitors, they are critical for covering rare metabolic disorders that otherwise attract limited therapeutic alternatives. Strensiq’s sales have shown steady year-over-year increases, with reports noting a 24% increase over a specific period, thus substantiating its role in the rare disease segment. Meanwhile, Kanuma has contributed modestly but consistently to quarterly revenue figures—a reflection of its niche yet indispensable role in treating lysosomal acid lipase deficiency. 

In quarterly earnings reports, Alexion’s revenue drivers have been dissected with a particular emphasis on these products. For instance, in one quarter, Soliris and Ultomiris collectively accounted for a massive proportion of overall revenue—driving multi-billion dollar sales and justifying the company’s strategic pricing and market positioning. Moreover, financial disclosures illustrate that while Soliris remains a strong revenue generator, Ultomiris is rapidly capturing market share, partly due to its improved administration profile and broader disease indications. 

Market Analysis

Comparison with Competitors 
Alexion’s sustained dominance in the rare disease sector, particularly in complement biology, has been a subject of market interest and competitive analysis: 

- Market Leadership Through Innovation: 
Historically, Alexion’s innovative approach—culminating in the development of Soliris as the first approved complement inhibitor—has set the company apart from its peers. Competing firms such as Apellis Pharmaceuticals (with its C3 inhibitor pegcetacopla) and other emerging players like Novartis, Roche, Amgen, and others have sought to challenge the market by developing candidate therapies that can either be more effective, offer alternative administration routes, or reduce dosing burdens. However, Alexion’s advanced clinical data, robust regulatory track record, and the high barrier to entry in the rare disease space have enabled it to maintain a competitive edge despite these challenges. 

- Dosing and Patient Convenience: 
Compared to many competitors that continue to rely on frequent intravenous infusions, the introduction of Ultomiris with its extended dosing interval represents a significant advantage. This improved patient convenience reduces the treatment burden and potentially enhances adherence and overall quality of life, further entrenching Alexion’s market position. 

- Portfolio Diversification and Competitive Moat: 
The company’s strategy of diversifying its portfolio to include both complement inhibition (Soliris and Ultomiris) and enzyme replacement therapies (Strensiq and Kanuma) enables it to fortify its competitive moat. In the context of biosimilar market challenges—particularly with Soliris—Alexion’s continuous product evolution (such as the development of Ultomiris) and expansion into metabolic disorders create overlapping revenue streams that are more resilient against aggressive pricing and competition from generic entrants. 

Factors Influencing Sales 
Several factors contribute to the impressive market performance of Alexion’s top-selling drugs: 

- Clinical Efficacy and Patient Outcomes: 
The transformative clinical benefits achieved with Soliris and Ultomiris—most notably by reducing hemolysis and improving survival in patients with PNH—drive physician prescribing and strong market adoption. The clinical data, which demonstrate significant gains in patient outcomes, underpin the therapies’ premium pricing and justify their extensive use despite high treatment costs. 

- Regulatory Approvals and Expansion of Indications: 
Both drugs have received multiple regulatory approvals across geographies, reinforcing their clinical benefits and safety profiles. The expansion of product indications, as seen with approvals for gMG and NMOSD in the case of Soliris, has broadened the target patient populations, thereby driving overall sales growth. 

- Pricing Strategies and Market Exclusivity: 
High list prices, supported by robust patent protections and limited biosimilar competition, have allowed Alexion to command top-tier pricing. For example, the annual cost for a patient on Soliris often exceeds $500,000, a factor that along with strong clinical performance, secures its marketplace position, even in the face of potential future competition. 

- Innovation in Administration: 
Ultomiris’s design improvements—specifically, its longer half-life enabling an extended dosing regimen—have not only driven sales but also enhanced market acceptance through increased convenience and improved quality of life for patients with chronic conditions. 

- Global Commercial Infrastructure and Strategic Partnerships: 
The company’s global presence, reinforced by its network of offices and strategic collaborations with other major biopharma companies, has allowed Alexion to effectively manage market entry and scale up sales across diverse regions. This global reach, combined with targeted marketing strategies, ensures high penetration of its top-selling products. 

Future Outlook

Pipeline and Upcoming Products 
While Soliris and Ultomiris continue to dominate current sales, Alexion’s future growth is being shaped by an extensive pipeline of innovative therapeutic candidates under development: 

- Complement Cascade Innovations: 
In addition to its flagship complement inhibitors, Alexion is actively developing next-generation therapies that target different stages of the complement cascade. Drugs such as an oral Factor D inhibitor and additional complement inhibitors are currently under investigation, signifying the company’s intent to cater to unmet needs and address limitations of current therapies. 

- Expansion in Metabolic Disorders and Enzyme Replacement Therapies: 
The success of Strensiq and Kanuma has paved the way for future enzyme replacement therapies targeting other life-threatening metabolic disorders. Ongoing mid-to-late-stage clinical programs indicate that additional products in this therapeutic area could bolster the company’s portfolio and contribute to further diversification of its revenue streams. 

- Late-Stage Assets and Novel Modalities: 
Beyond the established areas, Alexion is exploring innovative therapeutic modalities, including anti-neonatal Fc receptor (FcRn) antibodies for IgG-mediated diseases and copper-binding agents for Wilson disease. These assets, many of which are in late-stage clinical development, could open new market segment opportunities and further cement the company’s role in rare diseases. 

- Combination and Companion Therapies: 
The addition of danicopan, a promising small-molecule Factor D inhibitor acquired through the purchase of Achillion, serves as a companion drug that can be co-administered with Soliris or Ultomiris to potentially mitigate residual extravascular hemolysis. Its development not only reinforces the company’s commitment to improving existing treatment paradigms but also diversifies its clinical pipeline. 

Strategic Directions for Growth 
Looking ahead, Alexion’s growth strategy is multifaceted and centers on several key strategic directions: 

- Integration with AstraZeneca: 
The acquisition by AstraZeneca has introduced vast resources, global reach, and further integration into a broader portfolio that spans oncology, immunology, and rare diseases. This synergy is expected to drive innovation, streamline clinical development, and enhance commercialization efforts for both established products and new pipeline candidates. 

- Global Expansion and Market Penetration: 
Establishing a rare disease headquarters in Boston, along with significant operations in New York, New Haven, and global centers, positions Alexion to penetrate new markets and maximize the geographic reach of its therapies. As regulatory approval continues across varying regions, the potential for expansion in the EU, Japan, and other emerging markets remains substantial. 

- Investment in Research and Development: 
With over 20 clinical programs under development, Alexion’s continued focus on R&D is critical. The company’s expertise in complement biology is being leveraged to explore novel targets and innovative therapeutic modalities. As these efforts mature, they promise to enhance the company’s competitive advantage and drive future revenue growth. 

- Adaptive Pricing and Value-Based Care Models: 
Recognizing the high cost of innovative therapies, Alexion is actively engaged in strategies to justify premium pricing through demonstrable patient outcomes and value-based care models. With ongoing data collection and real-world evidence reinforcing clinical benefits, the company is well-positioned to navigate pricing pressures and reimbursement challenges in the rare disease space. 

Conclusion

Alexion Pharmaceuticals has built its reputation as a pioneering rare disease company largely on the commercial successes of its top-selling drugs, Soliris and Ultomiris. Soliris, the first C5 complement inhibitor approved for conditions such as PNH, aHUS, gMG, and NMOSD, has generated billions in revenue due to its transformative clinical benefits and high treatment costs. In parallel, Ultomiris, with its improved dosing regimen and robust market acceptance, has rapidly emerged as a critical revenue driver and a patient-friendly alternative. Supplementary therapies like Strensiq and Kanuma further broaden the company’s reach into metabolic disorders, enhancing its portfolio diversification.

From a market analysis standpoint, Alexion’s competitive position is reinforced not only by the clinical efficacy and market exclusivity of its lead products but also by strategic innovations in drug administration, global commercial infrastructure, and an adaptive regulatory approach. Despite facing emerging competition from firms like Apellis Pharmaceuticals and potential biosimilar threats, the company’s continued investment in innovative therapies, combined with its strategic alignment under AstraZeneca’s expansive umbrella, ensures that its clinical and commercial engine remains robust.

Looking forward, Alexion’s future outlook is bright. The company is actively expanding its pipeline with next-generation complement inhibitors, enzyme replacement therapies, and novel therapeutic modalities. Under the strategic direction of its new parent company, AstraZeneca, Alexion is set to leverage enhanced financial resources, global market reach, and an unwavering commitment to patient-centered outcomes to secure long-term growth. Its forward-thinking strategies—ranging from integration into a diversified portfolio, direct investments in R&D, and adaptive pricing models—all work in concert to ensure sustained market leadership in rare diseases.

In summary, Alexion Pharmaceuticals’ top-selling drugs—Soliris, Ultomiris, Strensiq, and Kanuma—are not only critical to its current commercial success but also serve as a solid foundation for future growth. Through a mixture of innovation, robust clinical performance, strategic global expansion, and integration with a powerhouse like AstraZeneca, Alexion is well-positioned to continue leading the rare disease market and driving transformative patient outcomes in the years ahead.

Curious to see how Eureka LS fits into your workflow? From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.